{"disease":{"id":"transthyretin-amyloid-polyneuropathy-attr-pn","name":"transthyretin amyloid polyneuropathy attr pn"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07223203","title":"TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":125,"lead_sponsor_name":"Alnylam Pharmaceuticals","has_results":false},{"nct_id":"NCT04828993","title":"The Effect Of Tafamidis Meglumine In Transthyretin Amyloid Polyneuropathy Patients","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":15,"lead_sponsor_name":"Pfizer","has_results":true}],"total":2},"guidelines":[],"source":"Drug Landscape verified database"}